The patent, entitled “Composition and method for transdermal delivery of cannabidiol (CBD) and delta9-tetrahydrocannabinol (THC)” expands Ovation’s intellectual property protection beyond its previously issued U.S. patent and significantly strengthens the Company’s growing international patent portfolio.
Ovation Science Inc. (CSE: OVAT) is positioned to benefit from U.S. cannabis rescheduling, which reduces regulatory barriers for cannabinoid-based topicals. The company's patented Invisicare® technology delivers 82% CBD bioavailability—far exceeding the 2–3% of competing topicals—and its THC-free formulations may qualify for potential Medicare reimbursement, creating expanded licensing opportunities in the U.S. market.
Ovation Science Inc. completed a non-brokered private placement to strengthen its financial position and support ongoing business development. The offering consisted of units made up of one common share and one warrant, with proceeds directed toward advancing company initiatives and general operations.
Ovation Science Inc. announced a non-brokered private placement to support its business growth and general working capital needs. The offering includes units comprised of one common share and one warrant, with finder’s fees payable in cash and warrants.
Ovation Science and Skinvisible Pharmaceuticals have expanded their partnership to advance patent-pending Invisicare® cannabinoid delivery technology for obesity and metabolic health. The collaboration leverages THC-V research, new patent protection, and the growing US$150B obesity therapy market.
Ovation Science Inc. announced an expanded license agreement with Planet 13 Holdings to bring its patented Invisicare® topical cannabis products to Florida's medical cannabis market. The products will be available across Planet 13's 33 Florida dispensary locations, marking Ovation's third active market alongside Nevada and Pennsylvania, with additional 2025 expansions planned in Missouri and Canada.
As recently featured in Wellness Master Club Magazine, Invibe®MD is redefining wellness with a science-backed, transdermal approach that goes beyond surface-level fixes.
Ovation Science Inc. launches its patented cannabis products in Pennsylvania through PA Options for Wellness, offering advanced transdermal and topical solutions powered by Invisicare® technology. With over 850,000 registered medical cannabis patients, this collaboration enhances patient care with research-backed, highly effective cannabinoid delivery systems.
Ovation Science announced the official launch of Ovation's topical product line in Nevada. These products, powered by Ovation's patented skin delivery technology, will be available in-store at Planet 13's SuperStore and online. The partnership aims to expand Planet 13's product offerings and leverage its production facility to manufacture the cannabis-derived topicals.
Ovation Science announced the signing of an exclusive licensing agreement for Ovation’s products for Canada with Ripco Processing Inc. a company based in Calgary, Alberta and founded by successful legal cannabis pioneers.
